Fate Therapeutics Inc Revenue Growth Rates (FATE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Fate Therapeutics Inc   (NASDAQ: FATE)
 

FATE's Revenue Growth by Quarter and Year

Fate Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FATE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 2.08
1st Quarter March 1.30
FY 3.38

FATEs Annual Revenue
Fate Therapeutics Inc 's Revenue in the fiscal year 2025 $ 6.65 millions
Fate Therapeutics Inc 's Revenue in the fiscal year 2024 $ 13.63 millions
Fate Therapeutics Inc 's Revenue in the fiscal year 2023 $ 63.53 millions
Fate Therapeutics Inc 's Revenue in the fiscal year 2022 $ 96.30 millions
Fate Therapeutics Inc 's Revenue in the fiscal year 2021 $ 55.85 millions




FATE Revenue second quarter 2026 Y/Y Growth Comment
Fate Therapeutics Inc reported Revenue growth of 9.01% year on year in the second quarter 2026, to $ 2.08 millions, this is lower than Fate Therapeutics Inc 's recent average Revenue rise of 50.12%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 37 other companies have achieved higher Revenue growth. While Fate Therapeutics Inc ' s Revenue increase of 9.01% ranks overall at the positon no. 1848 in the second quarter 2026.


FATE Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -26.34 % 10.71 % -96.21 %
3rd Quarter September - -43.32 % 58.25 % -87.05 %
2nd Quarter June 9.01 % -71.79 % 627.96 % -94.99 %
1st Quarter March -20.25 % -15.54 % -96.73 % 220.37 %
FY   - -51.21 % -78.55 % -

Financial Statements
Fate Therapeutics Inc 's second quarter 2026 Revenue $ 2.08 millions FATE's Income Statement
Fate Therapeutics Inc 's second quarter 2025 Revenue $ 1.91 millions Quarterly FATE's Income Statement


FATE Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -21.26 % -39.41 % -13.4 %
3rd Quarter September - -8.9 % -54.65 % 108.6 %
2nd Quarter June 60.15 % 17.18 % 250.78 % -98.42 %
1st Quarter March -5.11 % -12.37 % 14.88 % 32.96 %
FY (Year on Year)   - -51.21 % -78.55 % -


Back to FATE Growth rate Comparisons >> Back to FATE Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #38
Healthcare Sector #286
Overall #1848

Revenue Y/Y Growth Statistics
High Average Low
625.83 % 50.12 % -100 %
(Mar 31 2021)   (Dec 31 2013)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #38
Healthcare Sector #286
Overall #1848
Revenue Y/Y Growth Statistics
High Average Low
625.83 % 50.12 % -100 %
(Mar 31 2021)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Fate Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
251.79 % 21.43 % -98.42 %
(Jun 30 2024)  


FATE's II. Quarter Q/Q Revenue Comment
Fate Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 60.15%, to $ 2.08 millions, from $1.30 millions in the first quarter.
FATE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Fate Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 200.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #58
Overall #200
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #58
Overall #200
Revenue Q/Q Growth Statistics
High Average Low
251.79 % 21.43 % -98.42 %
(Jun 30 2024)  


FATE's II. Quarter Q/Q Revenue Comment
Fate Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 60.15%, to $ 2.08 millions, from $1.30 millions in the first quarter.
FATE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Fate Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 200.


Fate Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 6.49 $ 6.32 $ 6.65 $ 7.14 $ 8.47
Y / Y Revenue Growth (TTM) -23.36 % -52.64 % -51.24 % -46.92 % -31.23 %
Year on Year Revenue Growth Overall Ranking # 3494 # 113 # 1993 # 2275 # 2480
Seqeuential Revenue Change (TTM) 2.77 % -4.97 % -6.88 % -15.74 % -36.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 3543 # 2294 # 1354 # 845 # 69


Cumulative Revenue growth Comment
Fate Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Fate Therapeutics Inc 's annual Revenue drop would be -23.36% year on year to $6 millions.

In the Healthcare sector 475 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 113 to 3494.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 52
Healthcare Sector # 476
Overall # 3494

Revenue TTM Y/Y Growth Statistics
High Average Low
279.26 %
 37.95 %
-126.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 52
Sector # 482
S&P 500 # 3543
Cumulative Revenue growth Comment
Fate Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Fate Therapeutics Inc 's annual Revenue drop would be -23.36% year on year to $6 millions.

In the Healthcare sector 475 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 113 to 3494.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 52
Healthcare Sector # 476
Overall # 3494

Revenue TTM Y/Y Growth Statistics
High Average Low
279.26 %
37.95 %
-126.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 52
Sector # 482
S&P 500 # 3543




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FATE's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions


About Fate Therapeutics Inc Revenue Growth Rates (FATE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Fate Therapeutics Inc (CIK 1434316).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-347988
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Fate Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.